The use of methotrexate in steroid‐resistant systemic lupus erythematosus

Although the use of methotrexate (MTX) is gaining acceptance in the treatment of several connective tissue diseases, there is little evidence of its therapeutic value in systemic lupus erythematosus (SLE). We examined the response to MTX in patients with steroid‐resistant SLE in an open, unblinded s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis and rheumatism 1988-05, Vol.31 (5), p.612-615
Hauptverfasser:	Rothenberg, R. J., Graziano, F. M., Grandone, J. T., Goldberg, J. W., Bjarnason, D. F., Finesilver, A. G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Biological and medical sciences Clinical Trials as Topic Drug Resistance Gastrointestinal Diseases - chemically induced Humans Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - physiopathology Medical sciences Methotrexate - adverse effects Methotrexate - therapeutic use Middle Aged Mouth Diseases - chemically induced Pharmacology. Drug treatments Skin, nail, hair, dermoskeleton Steroids - therapeutic use Ulcer - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Although the use of methotrexate (MTX) is gaining acceptance in the treatment of several connective tissue diseases, there is little evidence of its therapeutic value in systemic lupus erythematosus (SLE). We examined the response to MTX in patients with steroid‐resistant SLE in an open, unblinded study. Of 10 SLE patients treated with MTX (7.5 mg/weekly), 7 showed improvement. The other 3 stopped therapy because of lack of response or because of side effects. Improvements were noted within 3 months in responding patients. These promising observations suggest that controlled studies of MTX for the treatment of SLE are justified.
ISSN:	0004-3591 1529-0131
DOI:	10.1002/art.1780310505